Phase I Trial of Selinexor (KPT-330) and Ifosfamide, Carboplatin, Etoposide (ICE) in Peripheral T-cell Lymphoma - Trial NCT03212937
Access comprehensive clinical trial information for NCT03212937 through Pure Global AI's free database. This Phase 1 trial is sponsored by National Cancer Centre, Singapore and is currently Completed. The study focuses on Peripheral T-cell Lymphoma. Target enrollment is 11 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
National Cancer Centre, Singapore
Timeline & Enrollment
Phase 1
Jul 01, 2016
Nov 01, 2020
Primary Outcome
Number of participants with treatment related dose limiting toxicity as assessed by NCI CTCAE v4.0
Summary
This is a single center, open-label, phase I trial with a standard 3+3 dose escalation schema
 to identify the maximum tolerated dose (MTD) of selinexor when combined with ICE. Once MTD is
 determined, there will be an expansion phase and tumor biopsies and peripheral blood will be
 taken pre and post selinexor to examine the study's biologic objectives.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT03212937
Non-Device Trial